Karo Pharma applies for delisting of the Company’s shares from Nasdaq Stockholm, in connection with the change of listing venue to Nasdaq First North Growth Market
The Board of Directors of Karo Pharma Aktiebolag (publ) (the “Company” or “Karo Pharma”) has today decided to apply for and submitted the application regarding delisting of the Company’s shares from Nasdaq Stockholm as well as decided to apply for listing of the Company’s shares on Nasdaq First North Growth Market (the “First North-listing”).As communicated on 15 December 2021, the Board considers that Nasdaq First North Growth Market, with its more suitable regulatory environment and lower cost of complying with continuing obligations, is a more appropriate listing venue for the Company